Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration

22-Dec-2008 - Switzerland

Generex Biotechnology Corporation and Pevion Biotech Ltd. have signed an agreement to work together to develop next-generation vaccines and immunotherapeutic products.

The initial goal of the collaboration will be to investigate synergies in the cancer vaccine approaches of the two companies. Both companies have in-depth experience in developing immunotherapeutic vaccines for cancers. A specific focus is oncogenes over-expressed in breast, ovarian, prostate, stomach and colon cancer as well as a variety of other malignancies. Within this collaboration, Generex wholly-owned immunotherapy subsidiary Antigen Express, Inc. combines Pevion Biotech's virosome technology with its own technology and is conducting trials in patients with breast, prostate and ovarian cancer. The combination of the two technologies will stimulate different portions of the immune system.

Pevion Biotech has developed products based upon its virosome technology to enhance the vaccine potency of various antigens. Antigen Express is developing next-generation immunotherapeutic peptides using technology to increase antigen-specific stimulation of CD4+ T helper cells. T helper cells are known to play an important role in regulating many branches of the immune system (e.g., cellular and antibody responses) and have been characterized as the 'generals' of the immune system. Virosomes are designed to interact with cells to elicit a robust immune response as well as to deliver antigens for specific immune recognition.

https://www.bionity.com/en/news/92973/generex-biotechnology-and-pevion-biotech-announce-plans-for-immunotherapeutic-vaccine-collaboration.html